Free Trial

Mereo BioPharma Group (MREO) Competitors

Mereo BioPharma Group logo
$2.13 -0.11 (-4.91%)
Closing price 10/21/2025 04:00 PM Eastern
Extended Trading
$2.14 +0.02 (+0.70%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MREO vs. ELVN, TRML, TRVI, IMNM, WVE, CVAC, MAZE, ATAI, CALT, and ARDX

Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Enliven Therapeutics (ELVN), Tourmaline Bio (TRML), Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), CureVac (CVAC), Maze Therapeutics (MAZE), atai Life Sciences (ATAI), Calliditas Therapeutics AB (publ) (CALT), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

Mereo BioPharma Group vs. Its Competitors

Mereo BioPharma Group (NASDAQ:MREO) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Enliven Therapeutics had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for Enliven Therapeutics and 3 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.43 beat Enliven Therapeutics' score of 0.16 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mereo BioPharma Group
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enliven Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mereo BioPharma Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Mereo BioPharma Group has higher revenue and earnings than Enliven Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group$10M33.87-$43.25M-$0.07-30.43
Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.60

Enliven Therapeutics' return on equity of -29.15% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma GroupN/A -80.00% -66.94%
Enliven Therapeutics N/A -29.15%-27.88%

Mereo BioPharma Group presently has a consensus target price of $7.40, suggesting a potential upside of 247.42%. Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 94.43%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mereo BioPharma Group
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats Mereo BioPharma Group on 9 of the 15 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MREO vs. The Competition

MetricMereo BioPharma GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$356.16M$3.47B$6.22B$10.67B
Dividend YieldN/A2.27%5.74%4.88%
P/E Ratio-30.4323.0629.1427.23
Price / Sales33.87496.95589.44132.72
Price / CashN/A47.5937.5161.65
Price / Book5.4610.6612.566.59
Net Income-$43.25M-$52.56M$3.32B$276.14M
7 Day Performance5.45%2.64%0.73%-0.72%
1 Month Performance15.14%13.86%7.29%2.47%
1 Year Performance-51.26%14.85%65.05%33.90%

Mereo BioPharma Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MREO
Mereo BioPharma Group
1.9742 of 5 stars
$2.13
-4.9%
$7.40
+247.4%
-53.0%$356.16M$10M-30.4340Gap Up
ELVN
Enliven Therapeutics
2.0589 of 5 stars
$20.68
-0.7%
$41.20
+99.2%
-26.6%$1.23BN/A-10.3450Insider Trade
TRML
Tourmaline Bio
1.6768 of 5 stars
$47.91
+0.1%
$45.65
-4.7%
+69.3%$1.23BN/A-13.9744Positive News
Short Interest ↓
TRVI
Trevi Therapeutics
2.4508 of 5 stars
$9.71
-2.8%
$21.75
+124.0%
+217.9%$1.22BN/A-23.1220
IMNM
Immunome
1.7678 of 5 stars
$14.25
+2.4%
$23.20
+62.8%
+40.6%$1.21B$9.04M-4.6340
WVE
WAVE Life Sciences
4.7361 of 5 stars
$7.79
+2.5%
$20.33
+161.0%
-48.0%$1.21B$108.30M-8.66240Analyst Forecast
CVAC
CureVac
3.5299 of 5 stars
$5.39
+0.2%
$6.83
+26.8%
+93.9%$1.21B$579.18M5.61880
MAZE
Maze Therapeutics
2.3716 of 5 stars
$28.57
+4.2%
$33.83
+18.4%
N/A$1.20B$167.50M0.00121Short Interest ↑
ATAI
atai Life Sciences
3.5666 of 5 stars
$5.40
+5.9%
$11.40
+111.1%
+389.2%$1.19B$310K-7.8380Gap Up
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ARDX
Ardelyx
4.2842 of 5 stars
$5.01
+1.4%
$11.70
+133.5%
-10.0%$1.19B$333.61M-21.7890

Related Companies and Tools


This page (NASDAQ:MREO) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners